ศูนย์วิจัย

ศูนย์วิจัยโรคติดเชื้อและสารเสพติด

รายละเอียดบุคลากร
พญ.อมราภรณ์ ฤกษ์เกษม

ชื่อ: พญ.อมราภรณ์ ฤกษ์เกษม

ตำแหน่ง: นักวิจัย
โทรศัพท์: 053 936148 ต่อ 309
Email: amaraporn.rer@cmu.ac.th

  • ประวัติการศึกษา
  • ประวัติการทำงาน
  • รางวัลที่เคยได้รับ
  • งานวิจัย
  • ผลงานวิจัยตีพิมพ์
  • ผลงานวิจัย
ลำดับ ปี การศึกษา
1 1999 Chiang Mai University, Chiang Mai, Thailand : Medicine, M.D.
2 2000 Chiang Mai University, Chiang Mai, Thailand : Post Graduate Education in Otolaryngology, Certificate
3 2004 Medical Council and Royal Collage of Otolaryngologist-Head and Neck surgeons, Thailand : Otolaryngology, Diploma
4 2019 Center for Clinical Epidemiology and Clinical Statistics, Faculty of Medicine, Chiang Mai University, Thailand : Clinical Epidemiology, Diploma
ลำดับ ปี การทำงาน
1 2003-2004 Lecturer in Department of Anatomy, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
2 2005-2018 Private medical practice at Lanna hospital and Leg Vein Clinic, Chiang Mai, Thailand.
3 Feb 2019-Present Researcher and study physician, Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand.
ลำดับ ปี รางวัล
1 2022 The University of Minnesota Center for Global Health and Social Responsibilities Global Engagement Grants program supports international global health collaborations
งานวิจัยที่สนใจ และ โครงการวิจัย

ลำดับ ชื่อ
1 2021 : Incidence and predictors of cardiovascular events and all-cause mortality in diabetes patients with peripheral arterial disease: 7 years cohort study
2 2022 : Vaginal/neovaginal microbiome alterations, gender affirmation therapy and implications for sexually transmitted infections in Thai transgender women
3 2022 : TOP-OP13NPD: Evaluation of the glycemic index of oligomeric parenteral nutrition formula in healthy adults.
4 2021 : MK-8591-024: Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Have Sex With Men and Are at High Risk for HIV-1 Infection
5 2022 : NN9535-4533: A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes (STRIDE)
6 2023 : A5403: Giving Standardized Estradiol Therapy In Transgender Women to Research Interactions with HIV Therapy: the GET IT RIgHT Study
7 2023 : ACTIV-2d/A5407: A Phase 3, multicenter, randomized, double-blind, 24-week study of the clinical and antiviral effect of S-217622 compared with placebo in non-hospitalized participants with COVID-19
8 2015 : A5332: Randomized Trial to Prevent Vascular Events in HIV – REPRIEVE.
9 2017 : HPTN083: A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), for Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women who have Sex with Men.
10 2018 : MK1439A: Comparison of MK-1439A and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus Type 1 (HIV-1)-Infected.
11 2018 : A5324: A Randomized, Double-Blinded, Placebo-Controlled Trial Comparing Antiretroviral Intensification with Maraviroc and Dolutegravir with No Intensification or Intensification with Dolutegravir Alone for the Treatment of Cognitive Impairment in HIV (InMIND).
12 2019 : HAND: The relationship between vascular disease, retinal degeneration, quality of life and human immunodeficiency virus-associated neurocognitive disorders in Northern Thai.
13 2020 : MTN035: Developing and evaluating Short-acting Innovations for rectal use. The DESIRE study.
14 2020 : A5375: An Open-Label, Phase II Pharmacokinetic Study to Evaluate Double-Dose Levonorgestrel Emergency Contraception in Combination with Efavirenz-Based Antiretroviral Therapy or Rifampicin-Containing Anti-Tuberculosis Therapy.
15 2020 : A5360: A Single-arm Study to Evaluate the Feasibility and Efficacy of a Minimal Monitoring Strategy to Deliver Pan-genotypic Ribavirin-free HCV Therapy to HCV Infected Populations who are HCV Treatment Naïve with Evidence of Active HCV Infection: The MINMON Study.
16 2022 : BIT225-010 : A Phase 2 Study of Human Immunodeficiency Virus-1 (HIV-1) Vpu Inhibitor, in Treatment Naïve HIV-1 Infected Individuals Commencing Dolutegravir-based Combination Antiretroviral Therapy (cART): Evaluation of Safety, Efficacy and Inflammatory and Immune Activation Markers
17 2022 : V503-049: A Phase 3, International, Multi-center, Randomized, Double-blind Placebo-controlleded clinical Trial to Study the Efficacy, Immunogenicity, and Safety of the 9vHPV Vaccine, a Multivalent L1 Virus-like Particle Vaccine, in the prevention of oral persistent infection with HPV Types 16, 18, 31, 33, 45, 52, or 58 in adult males, 20 to 45 years of age study.
18 2022 : A5379: B-ENHANCEMENT OF HBV VACCINATION IN PERSONS LIVING WITH HIV (BEe-HIVe): Evaluation of HEPLISAV-B.
โครงการวิจัย
ลำดับ ปี โครงการวิจัย
ลำดับ ผลงานวิจัย
1 ผลงานตีพิมพ์ใน Scopus
2 ผลงานตีพิมพ์ใน Pubmed

หน่วยสนับสนุนการวิจัย
Clinical Labolatory (CL)
Specimen Processing Unit (SPU)
Regulatory Compliance Unit (RCU)
กลุ่มงานวิเคราะห์ข้อมูลสถิติ
Pharmacy Unit
CAB
สำนักงานจริยธรรมการวิจัย